4-Aminopyridine (fampridine) effectively treats amlodipine poisoning : a case reportWILFFERT, B; BOSKMA, R. J; VAN DER VOORT, P. H. J et al.Journal of clinical pharmacy and therapeutics (Print). 2007, Vol 32, Num 6, pp 655-657, issn 0269-4727, 3 p.Article

Clinical Overview of Dalfampridine: An Agent With a Novel Mechanism of Action to Help With Gait DisturbancesEGEBERG, Michael D; OH, Caleb Y; BAINBRIDGE, Jacquelyn L et al.Clinical therapeutics. 2012, Vol 34, Num 11, pp 2185-2194, issn 0149-2918, 10 p.Article

Pharmacokinetics of ¹⁴C-Radioactivity After Oral Intake of a Single Dose of ¹⁴C-Labeled Fampridine (4-Aminopyridine) in Healthy VolunteersBLIGHT, Andrew R; HENNEY, Herbert R.Clinical therapeutics. 2009, Vol 31, Num 2, pp 328-335, issn 0149-2918, 8 p.Article

Dose comparison trial of sustained-release fampridine in multiple sclerosisGOODMAN, A. D; BROWN, T. R; COHEN, J. A et al.Neurology. 2008, Vol 71, Num 15, pp 1134-1141, issn 0028-3878, 8 p.Article

Steady-State Pharmacokinetics and Tolerability of Orally Administered Fampridine Sustained-Release 10-mg Tablets in Patients With Multiple Sclerosis: A 2-Week, Open-Label, Follow-Up StudyVOLLMER, Timothy; BLIGHT, Andrew R; HENNEY, Herbert R et al.Clinical therapeutics. 2009, Vol 31, Num 10, pp 2215-2223, issn 0149-2918, 9 p.Article

Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with multiple sclerosisWEIR, Scott; TORKIN, Risa; HENNEY, Herbert R et al.Current medical research and opinion. 2013, Vol 29, Num 12, pp 1627-1636, issn 0300-7995, 10 p.Article

Sustained-release fampridine and the role of ion channel dysfunction in multiple sclerosisKRISHNAN, Arun V; KIERNAN, Matthew C.Multiple sclerosis. 2013, Vol 19, Num 4, pp 385-391, issn 1352-4585, 7 p.Article

The Safety Profile of Dalfampridine Extended Release in Multiple Sclerosis Clinical TrialsCORNBLATH, David R; BIENEN, E. Jay; BLIGHT, Andrew R et al.Clinical therapeutics. 2012, Vol 34, Num 5, pp 1056-1069, issn 0149-2918, 14 p.Article

Sustained-release oral fampridine in multiple sclerosis : a randomised, double-blind, controlled trialGOODMAN, Andrew D; BROWN, Theodore R; KRUPP, Lauren B et al.Lancet (British edition). 2009, Vol 373, Num 9665, pp 732-738, issn 0140-6736, 7 p.Article

Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injuryPOTTER, P. J; HAYES, K. C; SEGAL, J. L et al.Journal of neurotrauma. 1998, Vol 15, Num 10, pp 837-849, issn 0897-7151Conference Paper

Dalfampridine Extended Release: In Multiple SclerosisCHWIEDUK, Claudine M; KEATING, Gillian M.CNS drugs. 2010, Vol 24, Num 10, pp 883-891, issn 1172-7047, 9 p.Article

Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injuryHAYES, K. C; KATZ, M. A; DEVANE, J. G et al.Journal of clinical pharmacology. 2003, Vol 43, Num 4, pp 379-385, issn 0091-2700, 7 p.Article

Pharmacokinetics and safety of multiple Oral doses of sustained-release 4-aminopyridine (fampridine-SR) in subjects with chronic, incomplete spinal cord InjuryHAYES, Keith C; POTTER, Patrick J; HSIEH, Jane T et al.Archives of physical medicine and rehabilitation. 2004, Vol 85, Num 1, pp 29-34, issn 0003-9993, 6 p.Article

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosisSCHWID, S. R; PETRIE, M. D; MCDERMOTT, M. P et al.Neurology. 1997, Vol 48, Num 4, pp 817-821, issn 0028-3878Article

fampridine (FAMPYRA°) : À peine moins de spasticité, plus de convulsions = Fampridine (FAMPYRA°) : barely less spasticity, more seizuresLa Revue Prescrire. 2011, Vol 31, Num 337, issn 0247-7750, p. 814Article

Intrathecal administration of 4-aminopyridine in chronic spinal injured patientsHALTER, J. A; BLIGHT, A. R; DONOVAN, W. H et al.Spinal cord. 2000, Vol 38, Num 12, pp 728-732, issn 1362-4393Article